Amarin's Vascepa showed CV benefit in patients with compromised renal function

• A post hoc subgroup analysis from the large-scale REDUCE-IT trial showed reduced cardiovascular (CV) events in patients with compromised renal function who received Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl). The results were presented at American Society of Nephrology Kidney Week.
• Adverse event rates were higher with decreasing eGFR (measure of kidney function), but total adverse events occurred at similar rates with VASCEPA versus placebo. A safety profile similar to the full REDUCE-IT study cohort was observed for VASCEPA compared with placebo across eGFR subgroups.
• The FDA OK'd the CV benefit claim in December 2019.
• https://seekingalpha.com/news/3625638-amarins-vascepa-showed-cv-benefit-in-patients-compromised-renal-function-in-reduce-study